A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall survival
Approximately 5 years
No
GSK Clinical Trials
Study Director
GlaxoSmithKline
Slovakia: State Institute for Drug Control
HYT105962
NCT00390806
December 2006
January 2013
Name | Location |
---|---|
GSK Investigational Site | Phoenix, Arizona 85013 - 4496 |
GSK Investigational Site | Little Rock, Arkansas 72205 |
GSK Investigational Site | Bakersfield, California 93309 |
GSK Investigational Site | Gainesville, Florida 32610 |
GSK Investigational Site | Indianapolis, Indiana 46260 |
GSK Investigational Site | Lexington, Kentucky 40536-0098 |
GSK Investigational Site | New Orleans, Louisiana 70112 |
GSK Investigational Site | Duluth, Minnesota 55805 |
GSK Investigational Site | St. Louis, Missouri 63141 |
GSK Investigational Site | Albuquerque, New Mexico 87109 |
GSK Investigational Site | Akron, Ohio 44304 |
GSK Investigational Site | Fort Worth, Texas 76104 |
GSK Investigational Site | Green Bay, Wisconsin 54301 |
GSK Investigational Site | Park Ridge, Illinois 60068 |
GSK Investigational Site | Columbia, South Carolina 29210 |
GSK Investigational Site | New York, New York 10021 |
GSK Investigational Site | Birmingham, Alabama 35209 |
GSK Investigational Site | Aurora, Colorado 80012 |
GSK Investigational Site | Kansas City, Kansas 66160 |
GSK Investigational Site | Hattiesburg, Mississippi 39401 |
GSK Investigational Site | Omaha, Nebraska 68131 |
GSK Investigational Site | Henderson, Nevada 89014 |
GSK Investigational Site | Oregon City, Oregon 97045 |
GSK Investigational Site | Seattle, Washington 98133 |